67.20

1.27% 0.84

After Hours: 67.22 0.02 +0.03%

Astrazeneca PLC (AZN)

Overview News Price History Option Chain Why AZN Down? Discussions Forecast Stock Split Dividend History

Astrazeneca PLC stock is traded at $67.20, with a volume of 4.14M. It is up +1.27% in the last 24 hours and down -10.46% over the past month. AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Previous Close:

$66.36

Open:

$66.69

24h Volume:

4.14M

Relative Volume:

0.80

Market Cap:

$206.50B

Revenue:

$51.21B

Net Income/Loss:

$6.50B

P/E Ratio:

33.94

EPS:

1.98

Net Cash Flow:

$6.76B

1W Performance:

+6.33%

1M Performance:

-10.46%

6M Performance:

-14.44%

1Y Performance:

+5.56%

1-Day Range:

$66.55

$67.32

1-Week Range:

$63.53

$67.32

52-Week Range:

$60.47

$87.67

Astrazeneca PLC Stock (AZN) Company Profile

Name

Astrazeneca PLC

Sector

Healthcare (1200)

Industry

Drug Manufacturers - Major (1)

Phone

44 20 3749 5000

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge

Employee

61,100

Twitter

@AstraZeneca

Next Earnings Date

2024-11-12

Latest SEC Filings

AZN's Discussions on Twitter

Compare AZN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AZN Astrazeneca PLC	67.20	206.50B	51.21B	6.50B	6.76B	1.98

Astrazeneca PLC Stock (AZN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-20-24	Upgrade	UBS	Sell → Neutral
Nov-06-24	Upgrade	Deutsche Bank	Sell → Hold
Sep-13-24	Downgrade	Deutsche Bank	Hold → Sell
May-30-24	Initiated	Goldman	Buy
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold
Dec-18-23	Initiated	HSBC Securities	Buy
Sep-25-23	Upgrade	Jefferies	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-05-23	Initiated	BMO Capital Markets	Outperform
Sep-15-22	Downgrade	Credit Suisse	Outperform → Neutral
Sep-07-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-29-22	Upgrade	Argus	Hold → Buy
Jun-14-22	Downgrade	UBS	Buy → Neutral
Feb-11-22	Upgrade	DZ Bank	Sell → Hold
Dec-07-21	Downgrade	Jefferies	Buy → Hold
Aug-12-21	Resumed	JP Morgan	Overweight
Apr-12-21	Downgrade	Argus	Buy → Hold
Mar-16-21	Upgrade	Jefferies	Hold → Buy
Feb-25-21	Upgrade	UBS	Neutral → Buy
Jan-15-21	Initiated	Deutsche Bank	Buy
Dec-07-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-30-20	Upgrade	UBS	Sell → Neutral
Nov-11-20	Upgrade	HSBC Securities	Reduce → Hold
Sep-29-20	Initiated	Berenberg	Buy
Nov-22-19	Initiated	SVB Leerink	Outperform
Oct-25-19	Upgrade	Liberum	Hold → Buy
Apr-02-19	Downgrade	UBS	Neutral → Sell
Feb-05-19	Initiated	Exane BNP Paribas	Outperform
Jan-25-19	Upgrade	Shore Capital	Hold → Buy
Dec-11-18	Resumed	Jefferies	Hold
Oct-09-18	Initiated	Guggenheim	Buy
Aug-16-18	Downgrade	Jefferies	Buy → Hold
Mar-19-18	Upgrade	Jefferies	Hold → Buy
Feb-06-18	Reiterated	Leerink Partners	Mkt Perform
Feb-05-18	Reiterated	Bernstein	Outperform
Jan-18-18	Reiterated	Leerink Partners	Mkt Perform
Dec-29-17	Upgrade	JP Morgan	Neutral → Overweight
Oct-16-17	Upgrade	Credit Suisse	Neutral → Outperform
Sep-25-17	Upgrade	Exane BNP Paribas	Neutral → Outperform
Sep-22-17	Upgrade	Bernstein	Mkt Perform → Outperform

View All

Astrazeneca PLC Stock (AZN) Latest News

Nov 27, 2024

AstraZeneca asthma drug more effective during attack than steroids, study finds - Reuters.com

Nov 27, 2024

Daiwa Securities Group Inc. Has $4.32 Million Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Nov 27, 2024

Nov 26, 2024

Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.

Nov 26, 2024

AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study - Yahoo Finance

Nov 26, 2024

Failure of AstraZeneca’s AZD4041 a blow for non-opioid OUD treatments - Clinical Trials Arena

Nov 26, 2024

Stock Watch: Investors Baulk At AstraZeneca And Bayer Q3 Updates - Citeline

Nov 26, 2024

Principal Street Partners LLC Purchases 8,986 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Nov 26, 2024

Sanders Capital LLC Has $1.17 Billion Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Nov 26, 2024

Quantbot Technologies LP Makes New Investment in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Nov 26, 2024

Bank of Montreal Can Increases Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Nov 26, 2024

Harvest Fund Management Co. Ltd Raises Stock Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Nov 26, 2024

Cerity Partners LLC Has $15.54 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Nov 26, 2024

AstraZeneca reports results from trial of combination therapy for prostate cancer - Clinical Trials Arena

Nov 26, 2024

AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Thrivent Financial for Lutherans - MarketBeat

Nov 26, 2024

AstraZeneca PLC Announces Positive High-Level Results from the Capitello-281 Phase III Trial - Marketscreener.com

Nov 26, 2024

Nov 25, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLCAZN - PR Newswire

Nov 25, 2024

AstraZeneca reports positive Phase 3 results for Truqap in prostate cancer (NASDAQ:AZN) - Seeking Alpha

Nov 25, 2024

AstraZeneca PLC (NASDAQ:AZN) Focuses on Growth in the U.S.: Is It the Best Time to Invest In AZN? - Insider Monkey

Nov 25, 2024

Fisher Asset Management LLC Purchases 524,175 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Nov 25, 2024

GCAR and AstraZeneca execute agreement to evaluate AZD1390 for glioblastoma - Clinical Trials Arena

Nov 25, 2024

Charles Schwab Investment Management Inc. Buys 8,830 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Nov 25, 2024